The in-demand program provides high-touch, holistic support for working parents and caregivers, addressing return-to-work challenges, emotional health support, and benefit navigation The in-demand program provides high-touch, holistic support for working parents and caregivers, addressing return-to-work challenges, emotional health support, and benefit navigation
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on Tuesday, March 11, 2025.
Pete Anevski, CEO of Progyny (PGNY), discusses his company's latest earnings and how it's poised for a "well-positioned" year. He notes general healthcare headwinds for the women's health company, though he expects Progyny to find new clients and retain current customers.
Progyny, Inc. (NASDAQ:PGNY ) Q4 2024 Earnings Conference Call February 27, 2025 4:45 PM ET Company Participants James Hart - Investor Relations Pete Anevski - Chief Executive Officer Mark Livingston - Chief Financial Officer Michael Sturmer - President Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Leerink Partners John Pinney - Canaccord Genuity Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Allen Lutz - Bank of America Sarah James - Cantor Constantine Davides - Citizens JMP Jenny Shen - BTIG Operator Good day, ladies and gentlemen. Welcome to the Progyny, Inc. Fourth Quarter Earnings Conference Call.
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m.
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building and women's health benefits solution, today announced the appointment of 30-year healthcare industry veteran Debra Morris to its board of directors, effective January 16, 2025.
Progyny shares have plummeted nearly 80% from 2021's peak, but management optimism and insider buying in December signal a potential turnaround during 2025. PGNY's valuation is deeply discounted, with strong fundamentals: $235M in cash, no debt, and 9.64% in trailing free cash flow yield. The stock's rare accumulation/momentum pattern since September and potential short squeeze kicker make it an attractive Buy.
SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.